Inflammation Linked to Lower Prostate Cancer Risk

This article originally appeared here.
Share this content:
Inflammation Linked to Lower Prostate Cancer Risk
Inflammation Linked to Lower Prostate Cancer Risk

(HealthDay News) — Among men with a negative biopsy for prostate cancer, acute and chronic inflammation at baseline correlate with a lower prostate cancer risk at repeat 2-year biopsy, according to a study published online Dec. 9 in Cancer.

Daniel M. Moreira, MD, from The Arthur Smith Institute for Urology in New Hyde Park, N.Y., and colleagues conducted a retrospective analysis involving 6,238 men aged 50 to 75 years with prostate-specific antigen levels between 2.5 and 10.0 ng/mL and a prior negative biopsy. The authors sought to examine whether baseline acute and chronic prostate inflammation was associated with the risk of subsequent prostate cancer detection. The association between inflammation in baseline prostate biopsies and positive two- and four-year repeat biopsies was assessed, with adjustment for baseline covariates.

The researchers found that acute inflammation, chronic inflammation, and both were detected in 1%, 63%, and 14% of baseline biopsies, respectively. The prevalence of prostate cancer was 14% at the 2-year biopsy. Both acute and chronic inflammation correlated significantly with a lower risk of prostate cancer at the 2-year biopsy (acute inflammation: odds ratio, 0.65 in univariate analysis and 0.75 on multivariate analysis; chronic inflammation: odds ratio, 0.61 on univariate analysis and 0.65 in multivariate analysis). Only acute inflammation was associated with lower prostate cancer risk at the time of the 4-year biopsy.

"Baseline acute and chronic inflammation were both found to be independently associated with a lower [prostate cancer] risk," the authors write. "From a clinical standpoint, inflammation in negative biopsies for [prostate cancer] may lower the risk of subsequent [prostate cancer] detection."

One author is employed by GlaxoSmithKline; several authors disclosed financial ties to the pharmaceutical industry.


  1. Moreira DM, Nickel JC, Gerber L, et al. Cancer. 2013;doi:10.1002/cncr.28349.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs